---
title: "Merck, Dr. Falk Pharma ink deal for rights to MK-8690, an investigational anti-CD30 ligand antibody"
description: "Merck, Dr. Falk Pharma ink deal for rights to MK-8690, an investigational anti-CD30 ligand antibody"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/264214346.md"
published_at: "2025-11-04T12:05:47.000Z"
---

# Merck, Dr. Falk Pharma ink deal for rights to MK-8690, an investigational anti-CD30 ligand antibody

### Related Stocks

- [MRK.US - Merck](https://longbridge.com/en/quote/MRK.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Merck & Co. Insider Sold Shares Worth $1,827,992, According to a Recent SEC Filing | 04:30 PM EST, 02/06/2026 (MT Newswires) -- Johannes Jacobus Oosthuizen, President, US Market, on February 06, 2026, sold | [Link](https://longbridge.com/en/news/275175518.md) |
| Merck's Pipeline Progress and Business Development Strategy Remain in Focus, Morgan Stanley Says | Merck's Pipeline Progress and Business Development Strategy Remain in Focus, Morgan Stanley Says | [Link](https://longbridge.com/en/news/274841608.md) |
| Lupin Signs Licensing Pact with Spektus Pharma to Commercialize DeslaFlex in Canada | Lupin Signs Licensing Pact with Spektus Pharma to Commercialize DeslaFlex in Canada | [Link](https://longbridge.com/en/news/276114633.md) |
| Assessing Merck (MRK) Valuation After Mixed Short Term Returns And Modest Earnings Multiple | Merck (MRK) has experienced mixed short-term performance, with a recent 0.9% decline. Despite this, its 1-year total ret | [Link](https://longbridge.com/en/news/272605734.md) |
| Mankind Pharma says tax penalty of 4.6 million rupees dropped | Mankind Pharma says tax penalty of 4.6 million rupees dropped | [Link](https://longbridge.com/en/news/276062947.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.